Inclusion criteria:

1.      Males and females aged 16-69 years (inclusive)
2.     Histologically confirmed classical Hodgkin lymphoma
3.  StageI or II with no mediastinal bulk disease or B-symptoms. Bulky disease at othersites is acceptable. Extranodal disease (single extranodal site (stage I) orcontiguous extranodal extension (stage II)) is acceptable
4.     ECOG performance status 0-2
5.     No previous treatment for Hodgkin lymphoma
6.     Fit to receive anthracycline based chemotherapy
7.     Creatinine clearance (measured or calculated)>40ml/min
8.     Total bilirubin 
9.     ALT or AST 
10.  Adequate bone marrow function: Neutrophils ≥1.0 x 10⁹/l, platelets ≥100 x 10⁹/l
11.  Haemoglobin ≥8g/dl
12.  Willing and able to comply with the requirements of the protocol, including contraceptive advice where applicable
13. Written informed consent

Exclusion criteria:

1.     Previous treatment for Hodgkin lymphoma

2. Infradiaphragmatic disease

3.     Nodular lymphocyte predominant Hodgkin lymphoma
4.     Absence of FDG-avid lymphoma lesions on baseline PET scan
5.     Age 70 years or over, or 15 years and under
6.     Other cancer diagnosed within the past 5 years apart from completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin
7.     Recurrent or persistent other cancer within the last 5 years irrespective of date of initial diagnosis
8.     Pre-existing sensory or motor peripheral neuropathy from any cause, grade ≥1
9.     History of, or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain
10.     Symptomatic neurologic disease compromising normal activities of daily living or requiring medications
11.  Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)
12.  Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first study drug dose
13.  Receiving or recently treated with any other investigational agent (within 4 weeks of study entry)
14.  Pregnant or breastfeeding women
15.   Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
16. Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration
17. Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A²VD hazardous